Ascendis Pharma Receives Committee For Medicinal Products For Human Use Opinion For TransCon PTH For Adults With Chronic Hypoparathyroidism
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma has received a positive opinion from the Committee For Medicinal Products For Human Use for TransCon PTH, a treatment for adults with chronic hypoparathyroidism. The final decision from the European Commission is expected within 67 days. If approved, the first launch in the European Union is planned for early 2024 in Germany.
September 14, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma's TransCon PTH has received a positive opinion, which could lead to approval and launch in the EU. This could potentially increase the company's market share and revenues.
The positive opinion for Ascendis Pharma's TransCon PTH is a significant step towards approval and launch in the EU. If approved, this could increase the company's market share and revenues, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100